Table 1.
Pharmacokinetic parameters of l-dopa after administering of placebo or entacapone 200 mg with different doses of l-dopa/carbidopa.
| Cmax (mg ml−1) | tmax (h) | AUC (0,12 h)(mg ml−1h) | ||||
|---|---|---|---|---|---|---|
| l-dopa/carbidopa dose (mg) | Placebo | Entacapone | Placebo | Entacapone | Placebo | Entacapone |
| 50/12.5 | 0.52 ± 0.29 | 0.38 ± 0.12* | 0.59 ± 0.41 | 0.94 ± 0.51 | 0.59 ± 0.12 | 0.76 ± 0.20*** |
| (-0.40, -0.02) | (0.15, 0.33) | |||||
| 100/10 | 0.83 ± 0.26 | 0.71 ± 0.12 | 0.75 ± 0.52 | 0.89 ± 0.56 | 1.21 ± 0.27 | 1.55 ± 0.32*** |
| (-0.29, 0.07) | (0.16, 0.35) | |||||
| 100/25 | 0.85 ± 0.31 | 0.72 ± 0.25 | 0.58 ± 0.25 | 1.16 ± 0.59** | 1.43 ± 0.34 | 1.93 ± 0.35*** |
| (-0.34, 0.02) | (0.20, 0.38) | |||||
| 150/37.5 | 1.52 ± 0.66 | 1.09 ± 0.31** | 0.58 ± 0.41 | 0.90 ± 0.50 | 2.40 ± 0.42 | 3.12 ± 0.80*** |
| (-0.50, -0.11) | (0.15, 0.34) | |||||
| 200/50 | 1.32 ± 0.24 | 1.16 ± 0.20 | 0.79 ± 0.63 | 1.61 ± 0.68* | 3.20 ± 0.43 | 4.45 ± 0.72*** |
| (-0.28, 0.04) | (0.24, 0.40) | |||||
| 250/25 | 1.76 ± 0.69 | 1.30 ± 0.23** | 1.02 ± 0.80 | 2.30 ± 1.58* | 3.68 ± 0.62 | 5.01 ± 0.94*** |
| (-0.40, -0.08) | (0.22, 0.38) | |||||
Values are means with s.d.; 95% confidence intervals on the differences between the mean values for entacapone vs placebo are given in parentheses, n = 14–16.
*
P < 0.05
**
P < 0.01
***
P < 0.001, ANOVA. Statistical significance was concluded if the 95% confidence interval excluded 0.